

Purified anti-human CD4 Antibody

Catalog# / Size	317401 / 25 µg 317402 / 100 µg
Clone	OKT4
Regulatory Status	RUO
Workshop	HCDM listed
Other Names	T4
Isotype	Mouse IgG2b, κ
Description	CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.

Product Details

Verified Reactivity	Human, Cynomolgus, Rhesus
Reported Reactivity	Chimpanzee
Antibody Type	Monoclonal
Host Species	Mouse
Immunogen	Human peripheral T cells
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C.
Application	FC - Quality tested IHC-F - Verified
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunohistochemistry, a concentration range of 5.0 - 10 µg/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454). In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4. ⁹
Application References	<ol style="list-style-type: none"> Knapp W, <i>et al.</i> 1989. Leucocyte Typing IV. Oxford University Press. New York. Reinherz EL, <i>et al.</i> 1979. <i>Proc. Natl. Acad. Sci.</i> 76:4061. Kmieciak M, <i>et al.</i> 2009. <i>J. Transl. Med.</i> 7:89. (FC) PubMed Cicin-Sain L, <i>et al.</i> 2010. <i>J. Immunol.</i> 184:6739. PubMed Rosenzweig M, <i>et al.</i> 2001. <i>J. Med. Primatol.</i> 30:36. Linder J, <i>et al.</i> 1987. <i>Am. J. Pathol.</i> 127:1. Boche D, <i>et al.</i> 1999. <i>J. Neurovirol.</i> 5:232. (IHC) Reinherz EL, <i>et al.</i> 1979. <i>Proc. Natl. Acad. Sci. USA.</i> 76:4061. (Immunogen)
(PubMed link indicates BioLegend citation)	

9. Lederman S, *et al.* 1991. *Mol Immunol.* 28:1171-81.

Product Citations

1. Gernoux G, *et al.* 2020. *Mol Ther.* 28:747. [PubMed](#)
2. Brinkmann CR, *et al.* 2018. *mSphere.* 3:e00616. [PubMed](#)
3. Ghosh S, *et al.* 2020. *Cell Reports.* 30(10):3434-3447. [PubMed](#)
4. Son YM, *et al.* 2020. *Eur J Immunol.* 50:1067. [PubMed](#)
5. Gao H, *et al.* 2021. *J Virol.* .: [PubMed](#)
6. Santos R, *et al.* 2017. *Nat Commun.* . 10.1038/s41467-017-01760-5. [PubMed](#)
7. Volchenkov R, *et al.* 2017. *Front Immunol.* 0.818055556. [PubMed](#)
8. Fletcher-Jones A, *et al.* 2019. *Elife.* 8:e44252. [PubMed](#)
9. Delgobo M, *et al.* 2021. *Front Immunol.* 12:584538. [PubMed](#)
10. Oberg HH, *et al.* 2020. *J Leukoc Biol.* 107:1081. [PubMed](#)
11. Harshe RP, *et al.* 2020. *Nat Commun.* 11:5894. [PubMed](#)
12. Li Y, *et al.* 2019. *Front Immunol.* 0.460416667. [PubMed](#)
13. Bovay A, *et al.* 2020. *Hum Vaccin Immunother.* 16:3103. [PubMed](#)
14. Ma F, *et al.* 2017. *Exp Cell Res.* 10.1016/j.yexcr.2017.10.011. [PubMed](#)
15. Martins MA, *et al.* 2017. *AIDS Res Hum Retroviruses.* 33:843. [PubMed](#)
16. Cobb DA, *et al.* 2022. *J Immunother Cancer.* 10.: [PubMed](#)
17. Kong R, *et al.* 2019. *Cell.* 178:567. [PubMed](#)
18. Martins M, *et al.* 2017. *PLoS Pathog.* 10.1371/journal.ppat.1006529. [PubMed](#)
19. Perez MD, *et al.* 2020. *Sci Rep.* 10:15748. [PubMed](#)
20. Wastyk HC, *et al.* 2021. *Cell.* 184(16):4137-4153.e14. [PubMed](#)
21. Alshafi N, *et al.* 2017. *J Virol.* 91:e00109. [PubMed](#)
22. Muhammad F, *et al.* 2020. *J Autoimmun.* 111:102441. [PubMed](#)
23. Ardain A, *et al.* 2019. *Nature.* 570:528. [PubMed](#)
24. Horn LA, *et al.* 2017. *Oncotarget.* 8:57964. [PubMed](#)
25. Cardoso V, *et al.* 2017. *Nature.* 549:277. [PubMed](#)
26. Li G, *et al.* 2022. *Mol Ther Oncolytics.* 24:887. [PubMed](#)
27. Majri SS, *et al.* 2018. *J Immunol.* 200:110. [PubMed](#)
28. Matos TR, *et al.* 2017. *J Clin Invest.* 127:4031. [PubMed](#)
29. Lou F, *et al.* 2020. *Immunity.* 53(1):204-216.e10. [PubMed](#)
30. Yang J, *et al.* 2020. *Nat Commun.* 11:4402. [PubMed](#)
31. Wang B, *et al.* 2018. *Mol Ther Nucleic Acids.* 0.548611111. [PubMed](#)
32. Martin E, *et al.* 2020. *JCI Insight.* :5. [PubMed](#)
33. Seyfarth J, *et al.* 2018. *Mol Cell Pediatr.* 5:2. [PubMed](#)
34. Prévost J, *et al.* 2018. *Virology.* 515:38:00. [PubMed](#)
35. Gernoux G, *et al.* 2021. *Mol Ther Methods Clin Dev.* 20:660. [PubMed](#)
36. Chiou SH, *et al.* 2021. *Immunity.* 54:586. [PubMed](#)

RRID

AB_571962 (BioLegend Cat. No. 317401)

AB_571963 (BioLegend Cat. No. 317402)

Antigen Details

Structure	Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution	T cell subset, majority of thymocytes, monocytes/macrophages
Function	MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor	MHC class II molecules, HIV gp120, IL-16
Cell Type	Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area	Immunology
Molecular Family	CD Molecules
Antigen References	1. Center D, <i>et al.</i> 1996. <i>Immunol. Today</i> 17:476. 2. Gaubin M, <i>et al.</i> 1996. <i>Eur. J. Clin. Chem. Clin. Biochem.</i> 34:723.
Gene ID	920

Related Protocols


[Immunohistochemistry Protocol for Frozen Sections](#)

[Cell Surface Flow Cytometry Staining Protocol](#)


Other Formats

Brilliant Violet 650™ anti-human CD4, Purified anti-human CD4, Biotin anti-human CD4, FITC anti-human CD4, PE anti-human CD4, PE/Cyanine5 anti-human CD4, PE/Cyanine7 anti-human CD4, APC anti-human CD4, APC/Cyanine7 anti-human CD4, Alexa Fluor® 488 anti-human CD4, Alexa Fluor® 647 anti-human CD4, Alexa Fluor® 700 anti-human CD4, Pacific Blue™ anti-human CD4, PerCP/Cyanine5.5 anti-human CD4, PerCP anti-human CD4, Brilliant Violet 421™ anti-human CD4, Brilliant Violet 605™ anti-human CD4, Brilliant Violet 711™ anti-human CD4, Brilliant Violet 785™ anti-human CD4, Brilliant Violet 510™ anti-human CD4, Brilliant Violet 570™ anti-human CD4, PE/Dazzle™ 594 anti-human CD4, TotalSeq™-A0922 anti-human CD4, Ultra-LEAF™ Purified anti-human CD4

Product Data



Human peripheral blood lymphocytes stained with purified OKT4, followed by anti-mouse IgGs FITC



Human frozen spleen tissue slices were fixed with 4% PFA for ten minutes and blocked with 5% FBS for 30 minutes. Then, the tissue was stained with 10 µg/mL of purified anti-human CD4 antibody (clone OKT4) overnight at 4°C. On the next day, tissue was incubated with Alexa Fluor® 594 Goat anti-mouse IgG (clone Poly4053, red). Nuclei were counter-stained with DAPI (blue). The image was scanned with a 10X objective and stitched with MetaMorph® software.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587